Global CAR T Cell Therapy Market Opportunity and Clinical Pipeline Insight 2024

  • No. of Pages: 330
  • Publish Date: November-2018
  • Category: Pharmaceutical and Healthcare
Electronic Access - Single User License
$2800
CD-ROM Mail Delivery
$3200
Hard Copy Mail Delivery
$3400
Electronic Access - Multi-User License
$4400

" Global CAR T Cell Therapy Market and Clinical Trials Insight 2024" Report Highlights:

 

  • CAR T-Cell Therapies Delivery Pipeline and Mechanism of Action

  • Sales Analysis of CAR - T Cell Therapy

  • CAR - T Cell Therapy Market Opportunity:  US$ 700 Million

  • CAR-T Cell Therapies Clinical Pipeline by Company, Indication and Phase:  236 Therapies

  • CAR-T Cell Therapies in Highest Phase:  Preclinical

  • Marketed  CAR-T Cell Therapies: 2 ( Yescarta and Kymriah)

  • Global Market Scenario of CAR T Cell Therapy

  • Global CAR T Cell Therapy Market Future Prospects

 

The research in immunotherapy has unlocked the way to harness an individual’s immune response to fight against the tumors and cancers. Many of the ideas have tried to make the use of natural killer cells or B cell, however, the research has not moved a past conceptual thinking. Immuno-oncology is an evolving treatment modality with the agents which being studied for their potential to provide the long term survival across a broad range of tumor types.

 

It is important to determine the advancement in this field and the use of new immunotherapies to achieve the best patient outcomes. The area of investigation is broad and includes the combining or sequencing the immunotherapies which target the immune pathways and sequencing an immunotherapeutic agent. CD-19 redirected chimeric antigen receptor is one of the immunotherapeutic modality which has been recently demonstrated the efficiency in re-inducing the remission in patients with multiply relapse B-acute lymphoblastic leukemia.

 

The global CAR-T cell therapy market boasts of a robust clinical pipeline under development with more than 200 products under various stages of development. As of 2018, only two products - Yescarta by Gilead Science and Kymriah by Novartis   have made it into the market. Both the products have been approved by the FDA for the treatment of acute lymphoblastic leukemia (ALL), a rare type of blood cancer.

 

The global CAR-T cell therapy market is dominated by US due to its early entry into the segment followed by the European Union. However, owing to the growing prevalence of Blood cancer in Europe, the CAR-T cell market might become a burgeoning market in the region during the forecast period. The global CAR-T cell market is bound to grow leaps and bound with a staggering CAGR of 40%, crossing the US$ 700 Million mark by 2024 driven by better market penetration, affordability and accessibility,.

 

KuicK Research report on the ‘global CAR-T cell Therapy market’ is a result of intensive study of the novel segment and its future market potential. The report has been made with key focus on the current market trends, CAR-T cell products and their superiority to traditional cancer therapy methods. The report also provides key insights into the market performance of existing CAR-T cell products, recent developments and market dynamics that might impact its future.  The report concludes with effective forecast data and future projections which clearly highlights it as one of the most promising market in the modern cancer therapy segment. 

Need custom market research solution? We can help you with that too.